Who
Daljit Singh Aurora
Officer
Company insider
Files Form 4 as: Chief Strategy Officer, Neumora Therapeutics; Chief Scientific Affairs Off, Dermira.
In numbers
- Trades disclosed
- 150
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $1.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Nov 2019
- Last trade
- 21 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Feb 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,553 at $0.00 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,055 at $0.00 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,553 at $0.00 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,055 at $0.00 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K20,553 at $0.72 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $33K20,553 at $1.59 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K21,055 at $0.72 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K21,055 at $1.60 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K20,553 at $0.72 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $33K20,553 at $1.59 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K21,055 at $0.72 | filing |
| 21 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $34K21,055 at $1.60 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $49K67,741 at $0.72 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —67,741 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —45,026 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —21,685 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Sold | $103K67,741 at $1.51 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code M | $16K21,685 at $0.72 | filing |
| 20 Aug 2026filed 21 Aug 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —67,741 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.